Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis

Objectives Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of haematology 2016-11, Vol.97 (5), p.416-429
Hauptverfasser: Ramsenthaler, Christina, Kane, Pauline, Gao, Wei, Siegert, Richard J., Edmonds, Polly M., Schey, Stephen A., Higginson, Irene J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 429
container_issue 5
container_start_page 416
container_title European journal of haematology
container_volume 97
creator Ramsenthaler, Christina
Kane, Pauline
Gao, Wei
Siegert, Richard J.
Edmonds, Polly M.
Schey, Stephen A.
Higginson, Irene J.
description Objectives Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM. Methods A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed. Results Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage. Conclusions Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.
doi_str_mv 10.1111/ejh.12790
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_ejh_12790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EJH12790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</originalsourceid><addsrcrecordid>eNp1kD1PwzAQQC0EoqUw8AeQV4a0thMnMRtCpQWVT_ExWk5yUV3iJIpTSv49htBu3HLS6d0bHkKnlIypmwmslmPKIkH20JCGhHgkJGIfDYkgzAuCgA7QkbUrQggTNDpEAxZxFgciHCL52MCnKqBMAVc5tp2p28pYrEtcq1ZD2Vq80e0Sm3XR6roAbDooKqMusHK0bcE4LMXOomGDVZlhA63yVKmKzmp7jA5yVVg4-dsj9Ho9fbmae4uH2c3V5cJLfRETT3GW5wnlMWdJxPyAioATBRFXGU0U8QXnQLkAdw546gPQNMhYEicKYs793B-h896bNpW1DeSybrRRTScpkT-RpIskfyM59qxn63ViINuR2yoOmPTARhfQ_W-S09v5Vun1H9oV-dp9qOZDhpEfcfl-P5OCvYVPzyGVd_43kCGA9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ramsenthaler, Christina ; Kane, Pauline ; Gao, Wei ; Siegert, Richard J. ; Edmonds, Polly M. ; Schey, Stephen A. ; Higginson, Irene J.</creator><creatorcontrib>Ramsenthaler, Christina ; Kane, Pauline ; Gao, Wei ; Siegert, Richard J. ; Edmonds, Polly M. ; Schey, Stephen A. ; Higginson, Irene J.</creatorcontrib><description>Objectives Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM. Methods A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed. Results Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage. Conclusions Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.12790</identifier><identifier>PMID: 27528496</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Humans ; multiple myeloma ; Multiple Myeloma - diagnosis ; Multiple Myeloma - epidemiology ; Neoplasm Staging ; Prevalence ; Quality of Life ; signs and symptoms ; Symptom Assessment ; symptom burden ; systematic review</subject><ispartof>European journal of haematology, 2016-11, Vol.97 (5), p.416-429</ispartof><rights>2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</citedby><cites>FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.12790$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.12790$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27528496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramsenthaler, Christina</creatorcontrib><creatorcontrib>Kane, Pauline</creatorcontrib><creatorcontrib>Gao, Wei</creatorcontrib><creatorcontrib>Siegert, Richard J.</creatorcontrib><creatorcontrib>Edmonds, Polly M.</creatorcontrib><creatorcontrib>Schey, Stephen A.</creatorcontrib><creatorcontrib>Higginson, Irene J.</creatorcontrib><title>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM. Methods A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed. Results Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage. Conclusions Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.</description><subject>Humans</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - epidemiology</subject><subject>Neoplasm Staging</subject><subject>Prevalence</subject><subject>Quality of Life</subject><subject>signs and symptoms</subject><subject>Symptom Assessment</subject><subject>symptom burden</subject><subject>systematic review</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQQC0EoqUw8AeQV4a0thMnMRtCpQWVT_ExWk5yUV3iJIpTSv49htBu3HLS6d0bHkKnlIypmwmslmPKIkH20JCGhHgkJGIfDYkgzAuCgA7QkbUrQggTNDpEAxZxFgciHCL52MCnKqBMAVc5tp2p28pYrEtcq1ZD2Vq80e0Sm3XR6roAbDooKqMusHK0bcE4LMXOomGDVZlhA63yVKmKzmp7jA5yVVg4-dsj9Ho9fbmae4uH2c3V5cJLfRETT3GW5wnlMWdJxPyAioATBRFXGU0U8QXnQLkAdw546gPQNMhYEicKYs793B-h896bNpW1DeSybrRRTScpkT-RpIskfyM59qxn63ViINuR2yoOmPTARhfQ_W-S09v5Vun1H9oV-dp9qOZDhpEfcfl-P5OCvYVPzyGVd_43kCGA9w</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Ramsenthaler, Christina</creator><creator>Kane, Pauline</creator><creator>Gao, Wei</creator><creator>Siegert, Richard J.</creator><creator>Edmonds, Polly M.</creator><creator>Schey, Stephen A.</creator><creator>Higginson, Irene J.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201611</creationdate><title>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</title><author>Ramsenthaler, Christina ; Kane, Pauline ; Gao, Wei ; Siegert, Richard J. ; Edmonds, Polly M. ; Schey, Stephen A. ; Higginson, Irene J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3980-a52ffb15852b723419450ae75ad1ba03955e159e94545c3ee1c4d2b8bae8553f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Humans</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - epidemiology</topic><topic>Neoplasm Staging</topic><topic>Prevalence</topic><topic>Quality of Life</topic><topic>signs and symptoms</topic><topic>Symptom Assessment</topic><topic>symptom burden</topic><topic>systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramsenthaler, Christina</creatorcontrib><creatorcontrib>Kane, Pauline</creatorcontrib><creatorcontrib>Gao, Wei</creatorcontrib><creatorcontrib>Siegert, Richard J.</creatorcontrib><creatorcontrib>Edmonds, Polly M.</creatorcontrib><creatorcontrib>Schey, Stephen A.</creatorcontrib><creatorcontrib>Higginson, Irene J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramsenthaler, Christina</au><au>Kane, Pauline</au><au>Gao, Wei</au><au>Siegert, Richard J.</au><au>Edmonds, Polly M.</au><au>Schey, Stephen A.</au><au>Higginson, Irene J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2016-11</date><risdate>2016</risdate><volume>97</volume><issue>5</issue><spage>416</spage><epage>429</epage><pages>416-429</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment‐related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM. Methods A systematic database and grey literature search were conducted in six databases. Random‐effects meta‐analysis with inverse variance weighting to pool prevalence data was performed. Results Thirty‐six studies were included of which 34 studies (N = 3023) provided data for meta‐analysis. Twenty‐seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1–99.2%), pain (73%, 39.9–91.7), constipation (65.2%, 22.9–92.2) and tingling in the hands/feet with 53.4% (0.4–99.7). The most common problems were decreased physical functioning (98.9%, 98.2–99.3), decreased cognitive functioning (80.2%, 40–96.1) and financial difficulties (78.4%, 39.1–95.4). These problems were present in newly diagnosed to advanced disease stage. Conclusions Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27528496</pmid><doi>10.1111/ejh.12790</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0902-4441
ispartof European journal of haematology, 2016-11, Vol.97 (5), p.416-429
issn 0902-4441
1600-0609
language eng
recordid cdi_crossref_primary_10_1111_ejh_12790
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Humans
multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - epidemiology
Neoplasm Staging
Prevalence
Quality of Life
signs and symptoms
Symptom Assessment
symptom burden
systematic review
title Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20symptoms%20in%20patients%20with%20multiple%20myeloma:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=European%20journal%20of%20haematology&rft.au=Ramsenthaler,%20Christina&rft.date=2016-11&rft.volume=97&rft.issue=5&rft.spage=416&rft.epage=429&rft.pages=416-429&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.12790&rft_dat=%3Cwiley_cross%3EEJH12790%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27528496&rfr_iscdi=true